Kenvue Inc. (NYSE:KVUE) Position Trimmed by Korea Investment CORP

Korea Investment CORP lowered its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 17.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 841,598 shares of the company's stock after selling 173,031 shares during the quarter. Korea Investment CORP's holdings in Kenvue were worth $17,968,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock valued at $4,665,908,000 after buying an additional 1,636,741 shares during the last quarter. State Street Corp raised its position in Kenvue by 16.8% during the third quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after acquiring an additional 18,283,473 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Kenvue by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company's stock worth $1,029,810,000 after purchasing an additional 399,846 shares during the last quarter. Harris Associates L P boosted its holdings in shares of Kenvue by 7.5% during the third quarter. Harris Associates L P now owns 31,459,511 shares of the company's stock worth $727,658,000 after purchasing an additional 2,186,114 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Kenvue by 2.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company's stock valued at $533,169,000 after purchasing an additional 561,570 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Evercore ISI started coverage on Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price target for the company. Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and lowered their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Finally, Citigroup decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $24.00.

Kenvue Stock Performance

Shares of NYSE:KVUE traded down $0.14 during trading on Tuesday, hitting $23.85. 11,113,788 shares of the company traded hands, compared to its average volume of 16,722,053. The stock has a market capitalization of $45.57 billion, a price-to-earnings ratio of 44.99, a PEG ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business's fifty day moving average is $22.38 and its 200-day moving average is $22.46.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.